Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Other Operating Expenses (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Other Operating Expenses for 2 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 103.92% to $6.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.2 million, a 226.01% increase, with the full-year FY2025 number at $17.2 million, up 226.01% from a year prior.
  • Other Operating Expenses was $6.1 million for Q4 2025 at Day One Biopharmaceuticals, up from $4.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $6.1 million in Q4 2025 to a low of $707000.0 in Q2 2024.